|
CHICAGO, Ill., June 2, 2007 - Pharmion Corporation (NASDAQ: PHRM) reported today the interim results of several Vidaza (azacitidine for injection) studies in the treatment of hematologic malignancies and advanced solid tumors.
|
www.drugs.com/clinical_trials/clinical-data-reported-vi...
www.drugs.com/clinical_trials/clinical-data-reported-vidaza-hematologic-malignancies-advanced-solid-tumors-1180.html
|
|
|
|
, today announced that it is will provide an update on the Phase I clinical trial of AVN944 in hematologic malignancies on Tuesday, June 19, 2007, after the close of the U.S. financial markets. The Company will also host a conference call on Wednesday, June 20, 2007 at 8 a.m. Eastern Time.
|
www.drugs.com/clinical_trials/avalon-updates-avn944-pha...
www.drugs.com/clinical_trials/avalon-updates-avn944-phase-hematologic-malignancies-trial-1279.html
|
|
|
|
Short description of the classification of Haematological Malignancies ... The Haematological Malignancies are a group of neoplasms that arise through malignant transformation of bone marrow derived cells. The great diversity seen in this group of disorders is a reflection of the complexity of normal haematopoeisis and...
|
www.hmds.org.uk/disorders.html
|
|
|
Hematologic malignancies are cancers of the blood that manifest themselves in several ways. The Hematology Program of Mayo Clinic Cancer Center has a strong tradition of advanced research focused on improving the diagnosis and treatment of hematologic diseases.
|
mayoresearch.mayo.edu/mayo/research/hematologic_maligna...
mayoresearch.mayo.edu/mayo/research/hematologic_malignancies/
|
|
The Medscape Journal ... Allergy & Clinical Immunology ... Diabetes & Endocrinology...
|
www.medscape.com/viewarticle/564100
|
|
Managing Infections in Patients With Hematologic Malignancies CME ... Special Considerations in the Management of Hematologic Malignancies: Subpopulations; Special Considerations in the Management of Hematologic Malignancies; Other Hematologic Malignancies; Emerging Infections, Vaccination Strategies, and Infection Control;
|
www.medscape.com/viewprogram/2765
|
|
The Hematologic Malignancies Program of the IU Simon Cancer Center offers comprehensive, state-of-the-art management for newly diagnosed or relapsed refractory acute and chronic leukemias and diagnosis and treatment of people with Hodgkin's disease and non-Hodgkin lymphoma, AIDS-related lymphomas, multiple myeloma or...
|
www.cancer.iu.edu/programs/hematologic/
www.cancer.iu.edu/programs/hematologic/
|
|
FDA approves romidepsin for cutaneous T-cell lymphoma ... The FDA has approved romidepsin for the treatment of cutaneous T-cell lymphoma in patients who have received at least one prior systemic therapy. ... Romidepsin (Istodax, Gloucester Pharmaceuticals), which is part of a new class of cancer drugs known as histone...
|
www.hemonctoday.com/Home.aspx?specialty=Hematologic%20M...
www.hemonctoday.com/Home.aspx?specialty=Hematologic%20Malignancies
|
|
The hematologic malignancies are a diverse group of disorders that are frequently considered together because they consist of clonal expansions of hematopoietic cells. The cell of origin of many of the hematologic malignancies is known.
|
www.health.am/cr/hematologic-malignancies/
www.health.am/cr/hematologic-malignancies/
|
|
